ACI 13th Annual Summit on Biosimilars & Innovator Biologics
June 29, 2022

On June 29, Axinn partners Jason Murata and David Silverstein spoke at ACI's 13th Summit on Biosimilars & Innovator Biologics held June 28-29 in Boston.

Jason Murata spoke on a panel entitled, "Advocating for Diversity in IP: Practical Ideas for Implementing Change.” Panelists discussed growing the awareness of pharmaceutical IP practitioners among underrepresented racial and ethnic groups, accelerating the advancement of a more diverse pharmaceutical IP community, and implementing organizational changes that promote diversity.

David Silverstein spoke on a panel entitled, "The Economics of Biosimilars: Improving Market Access, Sustainable Pricing and Reimbursement Policies.” Panelists discussed current market dynamics for biosimilars, the implications of insurers placing biosimilars on “primary tiers," and the implications of the Lower Drug Costs Now Act.

Click here for more information, including how to register. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.